Perspectum Group plc
We are a leading commercial-stage precision health company focused on democratizing high-quality care globally through the use of our proprietary digital technologies that enable healthcare providers to provide better care for patients. Our product portfolio comprises cloud-based AI-driven software that uses medical images to provide better decision support for the diagnosis, stratification and monitoring of patients with chronic metabolic diseases – especially liver diseases, multi-organ pathologies, cancer and other conditions that are poorly served by existing diagnostic modalities.
Our flagship AI-driven product, LiverMultiScan, has been cleared by the FDA for non-invasive diagnosis and monitoring of liver disorders, which may include nonalcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), a severe form of fatty liver disease. NASH is estimated to affect more than 250 million adults globally and more than 20 million adults in the United States. NAFLD is the most prevalent chronic liver disease, an epidemic affecting as much as 25% of the world’s population and has significant co-morbidities, including diabetes. There are about 90 million NAFLD patients in the United States. Approximately 23% of NAFLD patients eventually develop NASH.
MRCP+ is our AI-driven FDA-cleared product for digitalized, enhanced visualization and quantitative analysis of the biliary system driven by advanced image analysis and machine learning, a method of data analysis that automates analytical model building, and, to our knowledge, is the only clinically available tool of its kind.
Hepatica is our AI-driven FDA-cleared product for clinical use to process MR image (MRI) data sets to provide simultaneous evaluation of liver health (fibroinflammation and fat) and volumetry with AI-driven delineation of the liver and individual (Couinaud) segments in a single report of quantitative metrics.
CoverScan MD is our AI-driven product that has received Exceptional Use Authorization by the MHRA and addresses multi-organ pathologies, of relevance in “Long-COVID,” a disease associated with increased likelihood of developing diabetes and heart disease. We believe that CoverScan MD’s multi-organ approach to chronic disease evaluation and diagnosis has utility in aiding the management of pulmonary, cardiac, pancreatic, renal and splenic diseases at the individual organ level, as well as enabling the metabolic profiling of patients with Type 2 diabetes and metabolic syndrome at a multi-organ, multi-system level.
(Note: This IPO was scheduled for pricing on July 15, 2021, with a debut expected on Friday, July 16, 2021, but the deal did not get done. The timing of this IPO’s pricing is now described as “day to day” – in effect, postponed until further notice.)
|Industry:||Services - Medical Laboratories|
|Address||Gemini One 5520 John Smith Drive Oxford Business Park South Oxford, OX4 2LL Oxfordshire, England|
|Phone Number||+44 (0) 1865 655 343|
|View Prospectus:||Perspectum Group plc|
|Revenues||$9.26 mil (last 12 months)|
|Net Income||$-11.79 mil (last 12 months)|
|Price range||$15.00 - $17.00|
|Est. $ Volume||$75.2 mil|
|Manager / Joint Managers||Citigroup/ Barclays/ Stifel/ Canaccord Genuity|
|Expected To Trade:|
|Quiet Period Expiration Date:||Available only to Subscribers|
|Lock-Up Period Expiration Date:||Available only to Subscribers|
|SCOOP Rating||Available only to Subscribers|
|Rating Change||Available only to Subscribers|